CenterStar Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-16,000
Closed -$408K 375
2025
Q3
$408K Buy
+16,000
New +$395K 0.09% 191
2024
Q4
Sell
-22,500
Closed -$651K 359
2024
Q3
$651K Buy
+22,500
New +$656K 0.13% 135
2023
Q2
Sell
-13,900
Closed -$567K 362
2023
Q1
$567K Buy
+13,900
New +$600K 0.21% 93
2022
Q4
Hold
0
236
2022
Q3
Hold
0
-$683K 454
2022
Q2
Hold
0
147
2022
Q1
Hold
0
103
2021
Q3
Hold
0
-$589K 745
2021
Q2
Hold
0
215
2021
Q1
Hold
0
107
2020
Q1
Hold
0
-$11K 840
2019
Q4
Hold
0
342
2019
Q3
Hold
0
-$129K 552
2019
Q2
Hold
0
80
2019
Q1
Hold
0
-$2K 498
2018
Q4
Hold
0
453
2018
Q2
Hold
0
-$9K 1017
2018
Q1
Hold
0
857
2017
Q4
Hold
0
893

Other funds holding PFE

CenterStar Asset Management's PFE Position: Q1 2026 in Review

CenterStar Asset Management sold out of Pfizer (PFE) in Q1 2026, closing a stake of 9,156 shares — an estimated $244K sold.

CenterStar Asset Management first reported a position in PFE in Q2 2023 and held it in 2 quarters. The position peaked at $915K in Q2 2023. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • CenterStar Asset Management reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • CenterStar Asset Management sold 9,156 Pfizer shares in Q1 2026, an estimated $244K.
  • CenterStar Asset Management first reported a position in Pfizer in Q2 2023 and held it in 2 quarters.
  • CenterStar Asset Management's Pfizer position peaked at $915K in Q2 2023.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on CenterStar Asset Management's 13F filing for Q1 2026, filed 1 May 2026.